Immune cell therapy shows promising results for lymphoma patients

Physician investigators are working to bring immune cellular therapies to refractory diffuse large B-cell lymphoma patients. Promising results from the phase 1 portion of the ZUMA-1 study, which uses chimeric antigen receptor (CAR) modified T cells to treat b-cell lymphoma patients, have now been published.